UBS Initiates Coverage On Chemed with Buy Rating, Announces Price Target of $650
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.
UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.